Spots Global Cancer Trial Database for GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM
Official Title: A Study for Patients Newly Diagnosed With Glioblastoma Being Treated With Standard Radiotherapy and Temozolomide (TMZ) to Evaluate Tumor Response Via Liquid Biopsies (GRETeL)
Study ID: NCT05695976
Interventions
Study Description
Brief Summary: The purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (GBM), and to determine if plasma circulating tumor DNA (ctDNA) or cell free DNA (cfDNA) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States
Contact Details
Name: Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Affiliation: Duke University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
